Ixekizumab and ankylosing spondylitis

About 40% of patients with ankylosing spondyloarthritis treated tumor necrosis factor inhibitors do not achieve adequate disease control or symptom relief.

Ixekizumab improved signs and symptoms of AS at 16 weeks in patients who had an inadequate response to 1 or 2 TNF inhibitors. <i>Credit: ISM/Pr Jean-Denis LAREDO</i>

In these cases, ixekizumab that is a monoclonal antibody selectively targets IL-17A can be helpful. More ixekizumab than placebo patients report treatment-emergent adverse events, most of which are mild or moderate in severity. Serious adverse events occur with similar frequency across treatment arms.


Leave your comment


This site uses Akismet to reduce spam. Learn how your comment data is processed.

Notify of